US Stock Market Closed

Dashboard

Axsome Therapeutics, Inc. (AXSM)

Current

- (-)

After Hours

Rating & Fair Value

Fair Value Premium lock
Institutional Holdings

H

Financial Strength

H

Sustainable Growth

B

Industry Comparison

H

Management & Equity
Analyst Opinion

B

Leverage & Liquidity

H

Fundamental Variables

Rating Performance

FV Performance

About

Axsome Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its product candidates include AXS-05, AXS-07, AXS-09, AXS-12, and AXS-14 which are developing for multiple pain and primary care indications. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

CEO

Herriott Tabuteau

Employees

45

Industry

Neurology Biopharmaceuticals

Sector

Healthcare

Headquarters

New York

Exchange

NASDAQ

Summary Stats

Market Cap

2.47B

Revenue

-

Net Income

-

EPS

$0.00

Price-to-Earnings

-

Price-to-Book

-

Debt-to-Equity

-

News

Analyst Ratings

Price targets projected by 11 analysts

High

$210.00

Average

$146.91

Low

$65.00

Ratings calculated by 11 analysts

Buy

10

Hold

0

Sell

1

Last Dividend

Amount

-

Dividend Date

-

Frequency

-

Dividend Yield

Earnings

Most Recent Earnings

Last Earnings for Q3 2022

Last Earnings

Above by $0.01

Actual

-$1.07 +0.9%

Consensus

-1.08

Report Date

Year Ago

-0.93

Year Ago Change %

Down 15%

Actual vs Estimates

XX

xxx

Upcoming Estimates Unavailable

Expected EPS
-

-

Actual EPS
-

--

Competitors

star Favorites